UCB Study Highlights the Burden of Ocular Myasthenia Gravis by Chad Birt| Published on: Nov 12, 2026

UCB Study Highlights the Burden of Ocular Myasthenia Gravis by Chad Birt| Published on: Nov 12, 2026 Biopharmaceutical company UCB recently shared findings from a mixed-methods study examining the experiences and unmet needs of people living with ocular myasthenia gravis (oMG). The findings were presented at the 2026 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session. Anna Kole, Global Patient Engagement Lead for Myasthenia Gravis at UCB, discusses the findings and explains how patient perspectives could improve clinical research and care. https://checkrare.com/ucb-study-highlights-the-burden-of-ocular-myasthenia-gravis/